Presentation Material
FY2025
FY2025
Financial results for FY2025
- FY2025 Second Quarter Results Briefing Session -Movie-
- FY2025 Second Quarter Results Briefing Session - Material (1,550KB)
- FY2025 First Quarter Results Conference Call - Script (1,506KB)
- FY2025 First Quarter Results Conference Call - Material (1,150KB)
- FY2025 Third Quarter Results Briefing Session - Script (1,741KB)
- FY2025 Third Quarter Results Briefing Session - Material (1,281KB)
- FY2025 Second Quarter Results Briefing Session - Script (1,455KB)
Other Material
- Briefing Session Movie on the Agreement with Italfarmaco
- Briefing Session Script on the Agreement with Italfarmaco (2,175KB)
- Briefing Session Material on the Agreement with Italfarmaco (686KB)
- Information on the 44th J.P. Morgan Healthcare Conference Now Available (122KB)
- The 44th J.P.Morgan Healthcare Conference Presentation materials (2,448KB)
FY2024
FY2024
Financial results for FY2024
- [Updated] FY2024 Results Briefing Session - Material (1,363KB)
- FY2024 Results Briefing Session - Movie
- FY2024 Results Briefing Session - Script (2,659KB)
- [Updated] FY2024 Third Quarter Results Conference Call - Script (1,029KB)
- [Updated] FY2024 Third Quarter Results Conference Call - Material (684KB)
- FY2024 Second Quarter Results Briefing Session -Script- (2,092KB)
- FY2024 Second Quarter Results Briefing Session -Movie-
- FY2024 Second Quarter Results Briefing Session Material (1,419KB)
- FY2024 First Quarter Results Conference Call -Script- (1,615KB)
- FY2024 First Quarter Results Conference Call (869KB)
Other Material
FY2023
FY2023
Financial results for FY2023
- FY2023 Results Briefing Session -Script- (2,257KB)(2,257KB)
- FY2023 Results Briefing Session -Movie-
- FY2023 Results Briefing Session -Material- (1,196KB)(1,196KB)
- [Updated] Appendix to the Consolidated Financial Summary FY2023 (Flash report) (1,091KB)
- Appendix to the Consolidated Financial Summary FY2023 3rd Quarter (897KB)
- FY2023 First-Half Results Briefing Session -Script- (4,135KB)
- FY2023 First-Half Results Briefing Session -Movie-
- FY2023 First-Half Results Briefing Session -Material- (2,158KB)
- Appendix to the Consolidated Financial Summary FY2023 First-Half (726KB)
FY2022
FY2022
Financial results for FY2022
- FY2022 Second-Half Results Briefing Session -Movie-
- FY2022 Second-Half Results Briefing Session -Financial Results - (962KB)
- FY2022 Second-Half Results Briefing Session -Script- (8,153KB)
- FY2022 Second-Half Results Briefing Session - Business Highlights - (2,126KB)
- FY2022 First-Half Results Briefing Session -Movie-
- FY2022 First-Half Results Briefing Session -Script- (4,004KB)
FY2021
FY2021
Financial results for FY2021
- FY2021 Second-Half Results Briefing Session Q&A -Script- (322KB)
- FY2021 Second-Half Results Briefing Session -Script- (3,744KB)
- FY2021 Second-Half Results Briefing Session - Business Highlights - (1,589KB)
- FY2021 Second-Half Results Briefing Session - Financial Results - (898KB)
- FY2021 First-Half Results Briefing Session - Research and Development - (3,394KB)
- FY2021 First-Half Results Briefing Session - Financial Results - (1,366KB)
- FY2021 First-Half Results Briefing Session -Script- (4,496KB)
Other Material
- WORLDSymposium2021 Poster: A Comparison of Developmental Trajectories in Sibling Cases with Neuropathic MPS-II Receiving Conventional and Novel Enzyme Replacement Therapies (989KB)
- WORLDSymposium2021 Poster: Therapy for Mucopolysaccharidosis Type II with an Intravenous Blood-Brain Barrier-Crossing Enzyme (JR-141): Phase III Global Clinical Trial Design (474KB)
- WORLDSymposium2021 Poster:Exploration of the Efficacy of Pabinafusp-alfa (JR-141) on Neurocognitive Development in Hunter Syndrome (MPS-II): 52-week Data from Clinical Trials in Japan and Brazil (721KB)
- WORLDSymposium2021 Poster: Drug Delivery across the Blood-Brain Barrier and Resultant Reduction of Heparan Sulfate in the Cerebrospinal Fluid in the Patients with Hunter Syndrome (MPS-II): An Integrated Analysis of 25-Week Japanese and Brazilian Data on Pabinafusp Alfa (JR-141) (1,272KB)
- WORLDSymposium2021 Poster: Reduction of Heparan Sulfate in the Brain by Pabinafusp Alfa Results in Prevention of Neurodegeneration and Neurocognitive Impairment in a Mouse Model of Mucopolysaccharidosis II (1,113KB)
- WORLDSymposium2021 Poster: Phase I/II Clinical Trial Design for a Novel Therapy for Mucopolysaccharidosis Type I with an Intravenously Administered Blood-Brain Barrier-Crossing Enzyme (JR-171) (578KB)
- WORLDSymposium2021 Poster: Usefulness of Hexose Tetrasaccharide as a Biomarker for Monitoring Glycogen Accumulation in Peripheral Tissues and Brain in Pompe Disease (380KB)
- WORLDSympoisum2021 Poster: Non-Clinical Evaluation of a Blood-Brain Barrier-Penetrable N-Sulfoglucosamine Sulfohydrolase in a Mouse Model of Mucopolysaccharidosis IIIA (1,198KB)
- WORLDSymposium2021 Poster: Non-Clinical Evaluation of a Blood-Brain Barrier-Penetrable α-N-Sulfoglucosamine Sulfohydrolase in a Mouse Model of Mucopolysaccharidosis IIIB (1,078KB)
FY2020
FY2020
Financial results for FY2020
- FY2020 Results Briefing Session - Script - (4,603KB)
- FY2020 Results Briefing Session - Research and Development Highlights - (4,631KB)
- FY2020 Results Briefing Session - Financial Results - (2,003KB)
- FY2020 First-Half Results Briefing Session - Script - (3,749KB)
- FY2020 First-Half Results Briefing Session - Research and Development - (2,614KB)
- FY2020 First-Half Results Briefing Session - Financial Results - (1,169KB)
FY2019
FY2019
Financial results for FY2019
- FY2019 Results Briefing Session - Script - (4,930KB)
- FY2019 Results Briefing Session - Midterm Plan - (3,876KB)
- FY2019 Results Briefing Session - Research and Development Highlights - (1,347KB)
- FY2019 Results Briefing Session - Financial Results - (850KB)
- FY2019 First-Half Results Briefing Session - Research and Development - (1,770KB)
- FY2019 First-Half Results Briefing Session - Financial Results - (825KB)
- FY2019 First-Half Results Briefing Session - Script - (2,764KB)